TNF and inflammatory bowel disease: Tumor necrosis factor α (TNF-α) antagonists (infliximab, adalimumab, and certolizumab pegol) have demonstrated high efficacy in treating IBD, with all three agents being approved for CD and infliximab and adalimumab also approved for UC.